

# Individual Safety Report



\*3380751-0-00-01\*

R.W. JOHNSON PHARM. RES. INST. USA  
For use by user facilities,  
distributors and manufacturers for  
ADVERSE reporting

Page 1 of 2

ADVERSE REPORT #	PRIUSA199905930
ADVERSE REPORT #	
FRA Use Only	

## A. Patient information

1. Patient identifier 2-2	2. Age at time of event 32 yr	3. Sex <input checked="" type="checkbox"/> female <input type="checkbox"/> male	4. Weight UNK lbs UNK kgs
Date of birth: ??/??/??			

## B. Adverse event or product problem

1. <input checked="" type="checkbox"/> Adverse event and/or	<input type="checkbox"/> Product problem (e.g., defects/malfunctions)
2. Outcomes attributed to adverse event (check all that apply)	
<input checked="" type="checkbox"/> death ??/??/??	<input type="checkbox"/> disability
<input type="checkbox"/> life-threatening	<input type="checkbox"/> congenital anomaly
<input type="checkbox"/> hospitalization - initial or prolonged	<input type="checkbox"/> required intervention to prevent permanent impairment/damage
<input type="checkbox"/> other	
3. Date of event (month/day/yr)	4. Date of this report (month/day/yr)
??/??/??	10/19/99

## 5. Describe event or problem

Report published in 1987 Annual Report of the American Association of Poison Control Centers National Data Collection System (case 338). A 32 year-old patient died while taking glutethimide and acetaminophen/codeine. Serum acetaminophen level was <5 ug/mL. Patient had prehospital (cardiac and/or respiratory) arrest. Intent of ingestion was unknown.

Additional information received 12-Oct-99: This 32 year old woman presented to the emergency department comatose, apneic, pulseless, and without a blood pressure after ingesting an unknown quantity of glutethimide and acetaminophen with codeine. The time of the ingestion was unknown. The patient was intubated and placed on a respirator. Her blood pressure was supported with intravenous fluids and dopamine. Naloxone was given without response. Gastric lavage was performed and activated charcoal and a cathartic were administered. A toxicology screen revealed a plasma acetaminophen level of less than 5 mcg/mL. Acetylcysteine therapy was initiated. Serum glutethimide level was reported as "high" (Cont.)

## 6. Relevant test/laboratory data, including dates

Serum acetaminophen level was <5 ug/mL, serum glutethimide level was reported as "high" and rising (laboratory value not reported)

## 7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)

unknown

## C. Suspect medication(s)

1. Name (give labeled strength & manufacturer, if known)		3. Therapy dates (if unknown, give duration)	
#1 <b>TYLENOL WITH CODEINE (tablet) (ACETAMINOPHEN/CODE-)</b>		#1 ??/??/??	
#2 <b>GLUTETHIMIDE (GLUTETHIMIDE)</b>		#2 ??/??/??	
2. Dose, frequency & route used		4. Diagnosis for use (indication)	
#1 unk, oral		#1 UNKNOWN	
#2 unk, oral		#2 UNKNOWN	
6. Lot # (if known)		7. Exp. date (if known)	
#1		#1	
#2		#2	
9. NDC # - for product problems only (if known)			
10. Concomitant medical products and therapy dates (include treatment of event)			
No Concomitant Products Reported			

## G. All manufacturers

1. Contact office - name/address (& mailing site for devices)	2. Phone number
R.W. JOHNSON PHARM. RES. INST. USA DIV. OF ORTHO PHARMACEUTICAL CORP. 920 U.S. Route 202 P.O. Box 300 Raritan NJ 08859 USA ( Informing Unit )	908-704-4504
4. Date received by manufacturer (month/day/yr)	5. AINDA #
10/12/99	85-055
6. If IND, protocol #	IND #
	PLA #
7. Type of report (check all that apply)	pre-IND <input type="checkbox"/> yes
<input type="checkbox"/> 5-day <input checked="" type="checkbox"/> 15-day	OTC product <input type="checkbox"/> yes
<input type="checkbox"/> 10-day <input type="checkbox"/> periodic	
<input type="checkbox"/> Initial <input checked="" type="checkbox"/> follow-up # 1	
9. Mfr. report number	
PRIUSA199905930	

## 3. Report source (check all that apply)

- ☐ foreign
- ☐ study
- ☒ literature
- ☐ consumer
- ☒ health professional
- ☐ user facility
- ☐ company representative
- ☐ distributor
- ☐ other

## H. Adverse event term(s)

- 1) CARDIAC ARREST
- 2) APNOEA
- 3) COMA
- 4) RENAL FAILURE ACUTE
- 5) HEPATIC FAILURE
- 6) DISSEM. INTRAVASC.

## I. Initial reporter

1. Name, address & phone #	2. Health professional?	3. Occupation	4. Initial reporter also sent report to FDA
Dr. Toby L. Litovitz National Capital Poison Center Georgetown University Hospital 3900 Reservoir Road NW Washington, DC 20007 USA	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no	Physician	<input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> unk

Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.

R.W. JOHNSON PHARM. RES. INST. USA  
DIV. OF ORTHO PHARMACEUTICAL CORP.  
920 U.S. Route 202  
P.O. Box 300  
Raritan NJ 03869  
USA

Individual Safety Report



Continuation Sheet for FDA Form 3500 Form

Page 2 of 2

Mfr. report #: PRIUSA1999005930

Date of this report : 10/19/99

B. Adverse event or product problem

B.5 Describe event or problem (Cont...)

and rising (laboratory value not reported). The patient was admitted to the intensive care unit where dopamine and epinephrine were required to support her blood pressure. Two days post-ingestion, the patient's mental status started to clear and she was weaned off pressor agents. However, she became edematous, febrile, and developed disseminated intravascular coagulation. Fresh frozen plasma and packed cells were administered. Antibiotics were also started for a possible aspiration pneumonitis. Three days post-ingestion, the patient went into renal and hepatic failure. Her mental status became clouded and pancuronium was administered because of agitation. Peritoneal dialysis was started. The patient then developed ARDS and despite intensive supportive care, she expired 13 days after the ingestion. Exposure to medications was acute.

C. Suspect medication (Cont...)

Seq No.

C.1 Suspect medication

: 1

: TYLENOL WITH CODEINE (tablet) (ACETAMINOPHEN/CODEINE)

G. All manufacturers

8. Adverse event term(s)

- 6) DISSEM. INTRAVASC. COAGULATION
- 7) DYSPNOEA
- 8) PNEUMONITIS
- 9) AGITATION

Source of report (Literature):

Seq No.

Author

Journal title

Year

Edition

Page number

Article title

: 1

: Toby Litovitz

: American Journal of Emergency Medicine

: 88

: 6

: From 479 To 515

: 1987 Annual Report of the American Association of  
Poison Control Centers National Data Collection  
System

10/19/99